StockData
Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc. (LYEL) stock

LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$13.67−0.98 (-6.69%)

Close on Nov 17, 2026Market cap $334.99MP/E –Yield –

Lyell Immunopharma operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Lyell Immunopharma's operating cash flow for the twelve months ending Jun 30, 2026 was -$133.26M. For fiscal 2025 it was -$150.02M. The highest annual figure on record is $39.47M in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$150.02M–
FY2024Dec 31, 2024-$162.39M–
FY2023Dec 31, 2023-$163.69M–
FY2022Dec 31, 2022-$169.56M–
FY2021Dec 31, 2021-$126.25M–
FY2020Dec 31, 2020-$160.87M-507.5%
FY2019Dec 31, 2019$39.47M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$33.92M–
Q1 FY2026Mar 31, 2026-$38.51M–
Q4 FY2025Dec 31, 2025-$32.25M–
Q3 FY2025Sep 30, 2025-$28.58M–
Q2 FY2025Jun 30, 2025-$34.46M–
Q1 FY2025Mar 31, 2025-$54.74M–
Q4 FY2024Dec 31, 2024-$47.24M–
Q3 FY2024Sep 30, 2024-$35.04M–
Q2 FY2024Jun 30, 2024-$38.09M–
Q1 FY2024Mar 31, 2024-$42.02M–
Q4 FY2023Dec 31, 2023-$40.64M–
Q3 FY2023Sep 30, 2023-$37.69M–
Q2 FY2023Jun 30, 2023-$39.16M–
Q1 FY2023Mar 31, 2023-$46.21M–
Q4 FY2022Dec 31, 2022-$40.27M–
Q3 FY2022Sep 30, 2022-$37.10M–
Q2 FY2022Jun 30, 2022-$44.33M–
Q1 FY2022Mar 31, 2022-$47.85M–
Q4 FY2021Dec 31, 2021-$33.21M–
Q3 FY2021Sep 30, 2021-$25.49M–
Q2 FY2021Jun 30, 2021-$33.95M–
Q1 FY2021Mar 31, 2021-$33.60M–
Q4 FY2020Dec 31, 2020-$26.73M–
Q3 FY2020Sep 30, 2020-$21.63M–

More Lyell Immunopharma figures

See a number that looks wrong?